HomeWebinarsChanging Landscape of QC Testing for Emerging Therapies

Changing Landscape of QC Testing for Emerging Therapies


Key process goals are maintained to achieve scalable processes to ensure the reproducibility of the product. Market growth and application of emerging therapies have intensified the need for applied approaches to general safety, characterization, and efficacy testing that improves upon well-established techniques and streamlined testing. We provide an analysis of the current regulatory requirements for these molecules as well as the industry landscape and testing challenges. The use of state-of-the-art techniques to improve and expand existing testing processes to examine process product-related impurities, characterization, and viral safety provides a level of both safety and quality assurance that address current regulatory expectations.

In this webinar, you will learn:

  • The definition of emerging therapies and the regulatory guidance for such therapies
  • Traditional product characterization and biosafety methods and future scientific principles
  • Case studies to provide experiences of successful regulatory submission


Alison Armstrong, Ph.D.

Alison Armstrong, Ph.D.


Sr. Director, Technical and Scientific Solutions

Alison Armstrong is the global head of the field technology management team. She was appointed senior director, UK development services in 2009, and established a client-facing technology management team in 2015. This team is responsible for scientific and regulatory advice and fully supports clients. Alison has authored several articles on trends in biosafety testing and is a member of regulatory taskforce groups related to rapid technologies. She is an invited speaker at global conferences. She holds a Ph.D. in molecular virology from the University of Glasgow.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?